Xalkori
My Prescription
Payment
Select pharmacy
$24,541.84
Print or send this coupon to your phone
AlbertsonsPowered byAbout Xalkori
Drug Details
Crizotinib, marketed as Xalkori, is a targeted therapy medication used primarily to treat specific types of cancer, including metastatic non-small-cell lung cancer (NSCLC), advanced anaplastic large cell lymphoma (ALCL), and advanced inflammatory myofibroblastic tumor (IMT) when they feature certain mutations, such as ALK or ROS1. This oral medication is typically taken twice daily and works by inhibiting the activity of receptors in cells with these genetic mutations. By blocking these receptors, crizotinib effectively slows or stops the growth and spread of cancer cells. While the medication offers significant benefits in managing these cancers, it may cause side effects like nausea, diarrhea, and vision changes. Always consult healthcare professionals for personalized medical advice and before starting any new treatment.
Price history for Xalkori
60 Capsules, 200MG
Average retail price for Xalkori
Average SaveHealth price for Xalkori
Our price history data is based on aggregated prescription data collected from participating pharmacies in America. Our prescription data updates daily to reflect the latest price changes. If you notice a missing data point, it means there wasn't sufficient data available to generate a monetary value for that date.
*Retail prices are based on pharmacy claims data, and may not be accurate when we don't have enough claims.
Xalkori dosage forms
| Dosage | Quantity | Price from | Per unit |
|---|---|---|---|
| 200MG | 60 Capsules | $24,541.84 | $409.03 |
| 250MG | 60 Capsules | $24,541.84 | $409.03 |
Xalkori FAQs
Xalkori is used to treat certain types of non-small cell lung cancer (NSCLC) that are caused by specific genetic mutations, such as ALK-positive or ROS1-positive mutations.
The effectiveness of crizotinib compared to traditional chemotherapy depends on the specific type of cancer and its genetic characteristics. Crizotinib is often used for non-small cell lung cancer (NSCLC) with specific genetic mutations, such as ALK or ROS1 rearrangements. In patients with these mutations, crizotinib has shown to be more effective than standard chemotherapy in terms of response rates and progression-free survival. However, for cancers without these mutations, chemotherapy might still be the preferred treatment. It is important for patients to discuss with their oncologist to determine the most appropriate treatment based on their individual case.
The cost of Xalkori can vary depending on factors such as the pharmacy, location, insurance coverage, and dosage. It is recommended to contact a local pharmacy or healthcare provider for the most accurate and up-to-date pricing information. Additionally, patients may explore patient assistance programs or insurance options to help manage the cost.
Crizotinib has shown a significant success rate in treating patients with non-small cell lung cancer (NSCLC) that is ALK-positive. Clinical trials have demonstrated that crizotinib can lead to a response rate of approximately 60% to 70% in these patients. However, individual responses can vary, and the success rate may differ based on specific patient factors and the stage of the disease. It is important for patients to discuss their specific case with their healthcare provider to understand how crizotinib may work for them.
XALKORI is used to treat certain types of non-small cell lung cancer (NSCLC) that are caused by specific genetic mutations, such as ALK-positive or ROS1-positive NSCLC.